Business
The 2025 BPD Singapore Conference Has Concluded Successfully! Jointly Embarking on a New Journey for Global Development
The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference brought together leading biopharmaceutical companies and research institutions from Europe, North America, China, and the Asia-Pacific region. The conference aimed to facilitate exchanges and cooperation between Chinese and global biopharmaceutical enterprises and research institutions, and promote the a
About this update from Wuxi Xdc Cayman, Inc.
[{"type":"text","content":"SINGAPORE, Sept. 26, 2025 /PRNewswire/ -- The 2025 BPD (Biopharmaceutical Bioprocess Development) Singapore Summit, which co-hosted by WuXi XDC (Stock Code: 2268.HK), was successfully concluded from September 24-26, 2025. The conference brought together leading biopharmaceutical companies and research institutions from Europe, North America, China, and the Asia-Pacific region. The conference aimed to facilitate exchanges and cooperation between Chinese and global biopharmaceutical enterprises and research institutions, and promote the application of advanced process technologies in the manufacturing of innovative drugs.","length":632,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, Chairman of WuXi XDC, CEO of WuXi Biologics, delivered a speech at the conference. His speech closely focused on the core topics in the biopharmaceutical field, centered on the practical value brought by technological progress, and deeply explained how technological breakthroughs such as intelligent processes and the application of new raw materials achieve cost optimization and efficiency improvement, providing a clear path for the development of the industry. WuXi Biologics has always taken R&D as its core, continuously deepened technological innovation, and helped accelerate the R&D process of biopharmaceuticals.","length":647,"tagName":"p"},{"type":"text","content":"Dr. Jimmy Li, CEO of WuXi XDC, delivered the opening speech at the conference. He noted,"In recent years, the biopharmaceutical industry has developed rapidly, especially with complex therapies such as bioconjugates gradually entering a golden era. Accelerating and optimizing the journey of drugs from development to commercialization serves as a critical bridge connecting cutting-edge science to patient lives, and is key to successfully translating innovation into industrialized solutions. This conference to foster communication and cooperation among global biopharma, pharma, suppliers and research institutions, promote the application of advanced process technologies, and ultimately benefit patients worldwide, embodying our corporate vision-Linking Innovation to Health. "","length":793,"tagName":"p"},{"type":"text","content":"During this conference, WuXi XDC specially set up a forum titled "XDC Innovation and Development". The forum invited lea...